BEDROCK Act
The source supplies the latest action, but no lifecycle stage.
Latest action (27 Aug 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
The BEDROCK Act would direct the Secretary of Commerce to designate a senior official to lead federal efforts on strengthening U.S. biomanufacturing competitiveness. That official would identify barriers to private investment and commercialization, assess vulnerabilities in supply chains for critical biomanufacturing inputs (such as amino acids, enzymes, cell lines, and bioreactors), and evaluate reliance on foreign adversary countries or entities. The bill also requires a public web resource consolidating relevant federal information, a mapped "commercialization pathway" report on applicable federal regulatory processes, and designated points of contact at the FDA and EPA to help businesses navigate relevant rules. Voluntary industry practices on quality, supply-chain risk management, and information-sharing would also be identified and published.
The bill primarily affects biomanufacturing companies, suppliers of biological inputs, and investors, who would gain more transparency into federal processes and supply-chain risks. It also affects federal agencies (Commerce, FDA, EPA) by imposing new coordination, assessment, and reporting duties. Confidential business information and sensitive supply-chain data submitted voluntarily would be protected from public disclosure.
Introduced by Rep. Robert Latta on August 27, 2026, and referred to the House Committee on Energy and Commerce, the bill has not yet received committee action. Most of its requirements, including assessments and reports, would begin within one year of enactment and expire after five years unless renewed.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
27 Aug 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 10164 do?
- The BEDROCK Act would direct the Secretary of Commerce to designate a senior official to lead federal efforts on strengthening U.S. biomanufacturing competitiveness. That official would identify barriers to private investment and commercialization, assess vulnerabilities in supply chains for critical biomanufacturing inputs (such as amino acids, enzymes, cell lines, and bioreactors), and evaluate reliance on foreign adversary countries or entities. The bill also requires a public web resource consolidating relevant federal information, a mapped "commercialization pathway" report on applicable federal regulatory processes, and designated points of contact at the FDA and EPA to help businesses navigate relevant rules. Voluntary industry practices on quality, supply-chain risk management, and information-sharing would also be identified and published. The bill primarily affects biomanufacturing companies, suppliers of biological inputs, and investors, who would gain more transparency into federal processes and supply-chain risks. It also affects federal agencies (Commerce, FDA, EPA) by imposing new coordination, assessment, and reporting duties. Confidential business information and sensitive supply-chain data submitted voluntarily would be protected from public disclosure. Introduced by Rep. Robert Latta on August 27, 2026, and referred to the House Committee on Energy and Commerce, the bill has not yet received committee action. Most of its requirements, including assessments and reports, would begin within one year of enactment and expire after five years unless renewed.
- Has H.R. 10164 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10164. Check the latest action and official source below.
- Who sponsored H.R. 10164?
- H.R. 10164 was sponsored by Rep. Latta, Robert E. [R-OH-5] (R-OH), with 11 cosponsors.
- What's the latest action on H.R. 10164?
- Referred to the House Committee on Energy and Commerce. (27 Aug 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Latta, Robert E. [R-OH-5]
Collaboration on Adversarial Threats and Security Risks Act
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
STOP Nitazenes Act
Nuclear REFUEL (Recycling Efficient Fuels Utilizing Expedited Licensing) Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.